min) in the dark and stored in the frozen condition (Ϫ20°C) until subsequent assay.
Analytical Procedure The HPLC system consisted of HP1100 pump, HP1100 variable absorbance detector, HP1100 column heater and HP3395 integrator (Hewlett-Packard Inc., U.S.A.). Column (Hypersil ODS-2, 10 mm, 250ϫ4.6 mm) was purchased from Dalian Elite Scientific Instrument Co. Ltd. HPLC method and sample processing were modified as described by Kaikkonen J. et al. 2) The mobile phase was methanol : ethanol (9 : 1, v/v). The flow rate was 1.5 ml/min and the column temperature was heated to 30°C. The attenuation was 1 and the rate of record paper was 0.2 cm/min. UV detector was set at 275 nm. The plasma samples were processed as follows: frozen plasma samples were thawed at room temperature in the dark before analysis. Extractions were performed in 10 ml glass test tubes with stoppers. An aliquot of 50 ml internal standard (CoQ 9 , 24 mg/l in absolute ethanol) were added into 0.6 ml of plasma, and mixed for 10 s by a vortex mixer, and then the sample was deproteinized with 1.0 ml of methanol and mixed for 10 s by a vortex mixer. To this sample, 5 ml of hexane was added and mixed for 10 s by a vortex mixer and then oscillated for 10 min by an oscillator. The treated sample was statically placed in the dark for 10 min. 4.0 ml of hexane was transferred to a 10 ml glass test tube, and was dried at 25°C water bath under nitrogen gas stream. The residue was dissolved by 100 ml of absolute ethanol and then 20 ml of the solution was injected onto HPLC system.
An aliquot of 50 ml internal standard (CoQ 9 , 24 mg/l in absolute ethanol) and 100 ml of CoQ 10 solution (0.0, 1.2, 3.0, 6.0, 12.0, 18.0, 24.0 mg/l in absolute ethanol, respectively) were added to 0.6 ml of fresh plasma to prepare the calibration curves; same amount internal standard and 100 ml of CoQ 10 solution (1.2, 6.0, 24.0 mg/l in absolute ethanol, respectively) were added to 0.6 ml of fresh plasma to measure absolute recovery and inter-day relative standard deviation (R.S.D.). Calibrators and quality control extraction and other procedures were as described above. Calibration curve was constructed in the concentration range of 0.2-4.0 mg/l. The peak-area ratio increments of CoQ 10 /CoQ 9 were plotted as a function of the concentration of CoQ 10 . Where the peak-area ratio increment was the difference value of "peak-area ratio of total CoQ 10 /CoQ 9 " minus "peak-area ratio of endogenous CoQ 10 /CoQ 9 ". The absolute recoveries of CoQ 10 were estimated by comparison of the peak-area ratio increments (CoQ 10 /CoQ 9 ) after extraction from plasma to the peak-area ratios (CoQ 10 /CoQ 9 ) obtained after direct injection of a solution contained CoQ 9 and CoQ 10 in ethanol : hexane (1 : 6, v/v). The analysis was repeated five times at each level. Interday assay precision was determined by the analysis of the same concentration solutions on different days.
Pharmacokinetic Calculations Partial area under concentration-time curve (AUC p ) was calculated by trapezoidal rule. AUC p was divided into two parts: AUC 1 that was estimated from time-point 0 h to 36 h, and AUC 2 that was from 36 h to 412 h. AUC b (baseline AUC ) was the product of concentration at zero time point multiplied by total sampling time, and AUC in (increment AUC ) was the difference between AUC p and AUC b . AUC net increment proportion ( f net ) was obtained from the quotient between AUC in and AUC b . Relative bioavailability (F r ) between two formulations of CoQ 10 was obtained from quotient of mean AUC in between two products. Oral clearance including endogenous CoQ 10 (Cl/F, Cl denoted the total clearance of CoQ 10 from human body and F was absolute bioavailability) was estimated using the formula: Cl/FϭDose/(T i ϫC i ), where T i was the dose interval and C i was the steady state concentration at 348 h.
Statistic Analysis Single factor ANOVA (analysis of variance) was used for analysis of AUC 1 , AUC 2 , AUC p , concentration dataset (C 0 h-36 h , C 36 h-412 h ), T max and oral clearance, respectively. The paired t-test was used to compare AUC p with AUC b for increase in systemic exposure after oral administration of the two pharmaceutical preparations.
RESULTS

HPLC Method
Typical HPLC-UV chromatograms showed that the endogenous CoQ 10 peak in fresh plasma appeared around at 7.9 min ( Fig. 1A ) and the retention time of internal standard CoQ 9 was about at 6.4 min ( Fig. 1B ). Chromatograms in Figs. 1A and B were obtained from fresh plasma without or with supplement of CoQ 9 . Chromatogram in Fig. 1C was obtained from subject plasma that was supplemented with internal standard CoQ 9 .
The minimum concentration of CoQ 10 that could be detected in plasma was 0.02 mg/l. This was determined based on signal to noise ratio of approximately 3. The calibration curve was DYϭ1.6115CϪ0.2414, where DYϭthe peak-area ratio increment and Cϭsample concentration (rϭ0.9986). The absolute recoveries of CoQ 10 ranged from 94.0Ϯ3.2% to 97.8Ϯ6.2% as shown in Table 1 , and the precision of intraday and inter-day were shown Table 2 . The R.S.D. values ranged from 4.2% to 10.5% for intra-day assay, and from 4.3% to 12.1% for inter-day assay.
Plasma Concentrations and Pharmacokinetic Parameters The total coenzyme Q 10 concentrations in the human plasma following multiple oral 50 mg doses administered as coenzyme Q 10 sustained release tablets or regular ones were described in Table 3 . The mean concentrations of CoQ 10 (from 36 h to 412 h) following multiple oral administration sustained release tablets are slightly higher but not significantly ( pϾ0.05), compared to those administered with regular tablets, as shown in Fig. 2 . The pharmacokinetic parameters for both pharmaceutical preparations were listed as Table  4 , consisting of AUC p , AUC b , AUC in , f net , Cl/F and F r . Results showed that the AUC 1 (42.5Ϯ17.35 h · mg/l) of sustained release tablet was close to that (41.78Ϯ7.14 h · mg/l) of regular tablet. From 36 h, mean AUC 2 of sustained release tablets (613.46Ϯ194.26 h · mg/l) was larger but not significantly ( pϾ0.05) than that of regular tablets (477.68Ϯ94.39 h · mg/l), leading to an increase in the partial AUC p (655.96Ϯ208.78 vs. 519.45Ϯ97.50 h · mg/l). AUC p was significantly different from AUC b following oral administration of both products ( pϽ0.01 for sustained release tablets, pϽ0.01 for regular tablets), and the results showed that both pharmaceutical preparations improved the CoQ 10 levels. Both preparations increased the Net increment in AUC following oral administration of CoQ 10 sustained release tablets ( f net ϭ148.26Ϯ176.56%) or CoQ 10 regular tablets ( f net ϭ102.57Ϯ130.00%). Although the AUCs for sustained release tablets were larger than those of regular tablets, the difference was not statistically significant ( pϾ0.05). The oral clearances (Cl/F) between two pharmaceutical preparations were not significantly different (0.2284Ϯ0.3854 for sustained release tablets vs. 0.1506Ϯ0.0737 for regular tablets, pϾ0.05). The relative bioavailability (F r ) of CoQ 10 sustained release tablets was 143.0%, compared with CoQ 10 regular tablets.
DISSCUSION
Coenzyme Q 10 is almost insoluble in water, soluble in hot AUC 1 ϭarea under concentration-time curve from 0 h (before dosing) to 36 h; AUC 2 ϭarea under concentration-time curve from 36 h to 412 h; AUC p ϭAUC 1 ϩAUC 2 ; AUC b ϭendogenous CoQ 10 baseline AUC; AUC in ϭAUC p ϪAUC b ; f net ϭ(AUC in /AUC b )ϫ 100%, AUC net increment proportion; Cl/Fϭoral clearance of CoQ 10 including endogenous CoQ 10 ; F r ϭ(AUC in for sustained release tablet/AUC in for regular tablet)ϫ100%, relative bioavailability of sustained release tablet by comparing with regular tablet. ethanol and freely soluble in n-hexane. The determination method was established by improving the extraction recoveries. [5] [6] [7] The uses of methanol to precipitate protein in plasma and n-hexane to extract the CoQ 10 and CoQ 9 improved the extraction efficiency. CoQ 10 and the internal standard CoQ 9 are unstable under the light, thus all the samples were wrapped with aluminium foil and treatments were carried out under the illumination of yellow light or in the dark. In addition, CoQ 10 is also unstable at the high temperature. It is found that there are peaks of decomposed CoQ 10 in water bath at 40°C, but stable at 25°C or at 30°C under nitrogen gas stream for drying. Temperature of analytical column can influence the chromatogram peak shape, column set at 30°C produced chromatograms of good resolution rate and excellent peak shape for CoQ 10 and CoQ 9 .
CoQ 10 baseline in the morning was 0.88Ϯ0.48 mg/l (mean value, calculated from the both groups, range 0.21-1.81 mg/l). This is similar to the reported baseline range in European population (0.97Ϯ0.25, range 0.47-1.99 mg/l in men, and 0.84Ϯ0.22 range 0.24-1.92 mg/l in women 2) ). CoQ 10 levels reach up to 1.85Ϯ1.03 mg/l following 1 week dosing (50 mg/d) of CoQ 10 sustained release tablets and up to 1.37Ϯ0.74 mg/l following 1 week dosing (50 mg/d) of CoQ 10 regular tablets. CoQ 10 levels in the Europeans ranged from 0.5 to 2 mmol/l (0.4-1.7 mg/l) following single dosing of 100 mg, as described by Kaikonen J. 8) and Weis M. 9) It is already well known that plasma CoQ 10 concentrations are highly dependent on serum lipoproteins (cholesterol levels), which are the carriers of CoQ 10 in the circulation. CoQ 10 concentrations include both endogenous and exogenous levels. Diet can influence the endogenous plasma CoQ 10 levels because CoQ 10 may be absorbed from the food. For humans, the major dietary sources of CoQ 10 are meats, fish, and some vegetables. The motion, time of day, human race, age, gender, drug dosage forms may also influence the levels of CoQ 10 . The endogenous levels of CoQ 10 in different human race may be different, due to the different diet, size, etc. Furthermore, the plasma CoQ 10 levels are higher 9) in men than in women. Endogenous CoQ 10 fluctuates at different time-points in the day and night. When a small amount of CoQ 10 was administered to subject, the elimination phase may not so clear in the concentration-time curve, thus leading to difficulty for evaluation of exact elimination rate constant. Very high dosing of CoQ 10 to humans is not suitable due to medical, ethic and legislation reasons. However, concentrations following multiple dosing can provide a clear profile of CoQ 10 in plasma, these will provide a useful information for clinical practice. The concentration-time profiles for both formulations showed a slow rise in concentrations. This may be due to the rapid distribution of CoQ 10 into cells and tissues and does not necessarily mean that CoQ 10 was sparsely absorbed from gastric intestine tract. In humans, CoQ 10 is found in relatively high concentrations in the heart, liver, kidney and pancreas. Total body content of CoQ 10 has been estimated to be 0.5-1.5 g. 4, 10) The intracellular distribution of CoQ 10 is described as follows: nucleus 25-30%; mitochondria 40-50% (inner mitochondria membrane); microsomal 15-20%; cytosolic 5-10%.
Following ingestion of 100 mg of CoQ 10 , 4) peak plasma levels occur between 5 and 10 h, indicating a slow absorption from the gastrointestinal tract due to its high molecular weight and low water solubility. After the initial dose for both formulations, the C max (1.20 mg/l vs. 1.15 mg/l) and T max (6 h vs. 6 h) were very similar. This suggests that the sustained release did not significantly delay the absorption rate, and indicated that dissolution is probably the more important factor rather than release and the absorption rate like that reported 4) seemed slow. Mean concentrations of CoQ 10 following multiple oral administration sustained release tablets are higher but not significantly, than that after regular tablets. Similar results were obtained from comparison of AUCs, though higher mean values for sustained release tablets are found in AUC 2 , AUC p , AUC in compared to regular tablets, no significant differences were observed between the two pharmaceutical preparations. The paired t-test results demonstrated that both pharmaceutical preparations improved the systemic exposure of CoQ 10 by comparing AUC p with AUC b .
In conclusion, the oral administration of both CoQ 10 tablets improved the CoQ 10 plasma levels and systemic exposure in Asian men. The morning baseline CoQ 10 level of 0.88Ϯ0.48 mg/l in Asian men was similar to that in Europeans. Following 1 week 50 mg/d dosing of CoQ 10 , plasma CoQ 10 concentrations increased to 1.85Ϯ1.03 mg/l for sustained release tablets and up to 1.37Ϯ0.74 mg/l for regular tablets. The net increment proportion in AUC for sustained release and regular tablets are 148.26Ϯ176.56%, 102.57Ϯ 130.00%, respectively. Although the sustained release preparation provided longer systemic exposure of CoQ 10 , the effect is not statistically significant compared to the regular preparation.
